RQIH vs. BPCR, TV2H, KLSO, KRM, VCAP, WHI, NBS, ADA, QBT, and FKE
Should you be buying R&Q Insurance stock or one of its competitors? The main competitors of R&Q Insurance include BioPharma Credit (BPCR), Thames Ventures VCT 2 Healthcare Shs (TV2H), Kelso Group (KLSO), KRM22 (KRM), Vector Capital (VCAP), WH Ireland Group (WHI), Nationwide Building Society (NBS), Adams (ADA), Quantum Blockchain Technologies (QBT), and Fiske (FKE). These companies are all part of the "financial services" sector.
R&Q Insurance (LON:RQIH) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, community ranking, dividends, earnings, analyst recommendations, valuation and risk.
BioPharma Credit has lower revenue, but higher earnings than R&Q Insurance. R&Q Insurance is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.
R&Q Insurance received 34 more outperform votes than BioPharma Credit when rated by MarketBeat users. However, 64.62% of users gave BioPharma Credit an outperform vote while only 59.00% of users gave R&Q Insurance an outperform vote.
R&Q Insurance has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, BioPharma Credit has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500.
BioPharma Credit has a net margin of 83.84% compared to R&Q Insurance's net margin of -118.70%. BioPharma Credit's return on equity of 13.65% beat R&Q Insurance's return on equity.
In the previous week, R&Q Insurance and R&Q Insurance both had 1 articles in the media. BioPharma Credit's average media sentiment score of 0.80 beat R&Q Insurance's score of 0.42 indicating that BioPharma Credit is being referred to more favorably in the news media.
R&Q Insurance pays an annual dividend of GBX 2 per share and has a dividend yield of 79.7%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 799.1%. R&Q Insurance pays out -241.0% of its earnings in the form of a dividend. BioPharma Credit pays out 5,384.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
69.3% of R&Q Insurance shares are held by institutional investors. Comparatively, 38.7% of BioPharma Credit shares are held by institutional investors. 24.3% of R&Q Insurance shares are held by company insiders. Comparatively, 7.8% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
BioPharma Credit beats R&Q Insurance on 10 of the 16 factors compared between the two stocks.
Get R&Q Insurance News Delivered to You Automatically
Sign up to receive the latest news and ratings for RQIH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RQIH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
R&Q Insurance Competitors List
Related Companies and Tools
